Clinical activity and tolerability of trazodone, mianserin, and amitriptyline in elderly subjects with major depression: A controlled multicenter trial

A. C. Altamura, M. C. Mauri, N. Rudas, B. Carpiniello, R. Montanini, M. Perini, P. L. Scapicchio, C. Hadjchristos, G. Carucci, M. Minervini, A. D'Aloise, A. Malinconico, E. Aguglia, R. De Vanna, R. D'Aronco

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The aim of this multicenter study was to compare trazodone (TRA) with two reference drugs, amitriptyline (AMI) and mianserin (MIA), under double-blind conditions, in an elderly population, to ascertain age-related patterns for efficacy and tolerability. One hundred six elderly depressed inpatients, ranging in age from 60 to 83 years, diagnosed as having major depression according to DMS-III, were treated with 75 mg AMI (37 patients), 60 mg MIA (33 patients) or 150 mg TRA (36 patients) p.o. t.i.d. for 5 weeks. There were no differences in the clinical outcome among the three groups of patients at the end of the trial, with a significant amelioration (p <0.01) for the Hamilton Rating Scale for Depression (HRS-D) and the Geriatric Depression Scale (GDS). TRA showed a lower overall prevalence of side effects than AMI or MIA, particularly for anticholinergic (p = 0.03 vs. AMI) and cardiovascular (p = 0.05 vs. MIA) effects. For these data GDS seems to be most reliable in detecting changes in elderly depressive symptomatology; moreover a comparable therapeutic response (among the three drugs) but a better tolerance for atypical antidepressants, particularly TRA, make advisable the use of the latter drug in the elderly population.

Original languageEnglish
JournalClinical Neuropharmacology
Volume12
Issue numberSUPPL. 1
Publication statusPublished - 1989

Fingerprint

Trazodone
Mianserin
Amitriptyline
Multicenter Studies
Geriatrics
Second-Generation Antidepressive Agents
Pharmaceutical Preparations
Cholinergic Antagonists
Population
Inpatients

ASJC Scopus subject areas

  • Clinical Neurology
  • Pharmacology (medical)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Clinical activity and tolerability of trazodone, mianserin, and amitriptyline in elderly subjects with major depression : A controlled multicenter trial. / Altamura, A. C.; Mauri, M. C.; Rudas, N.; Carpiniello, B.; Montanini, R.; Perini, M.; Scapicchio, P. L.; Hadjchristos, C.; Carucci, G.; Minervini, M.; D'Aloise, A.; Malinconico, A.; Aguglia, E.; De Vanna, R.; D'Aronco, R.

In: Clinical Neuropharmacology, Vol. 12, No. SUPPL. 1, 1989.

Research output: Contribution to journalArticle

Altamura, AC, Mauri, MC, Rudas, N, Carpiniello, B, Montanini, R, Perini, M, Scapicchio, PL, Hadjchristos, C, Carucci, G, Minervini, M, D'Aloise, A, Malinconico, A, Aguglia, E, De Vanna, R & D'Aronco, R 1989, 'Clinical activity and tolerability of trazodone, mianserin, and amitriptyline in elderly subjects with major depression: A controlled multicenter trial', Clinical Neuropharmacology, vol. 12, no. SUPPL. 1.
Altamura, A. C. ; Mauri, M. C. ; Rudas, N. ; Carpiniello, B. ; Montanini, R. ; Perini, M. ; Scapicchio, P. L. ; Hadjchristos, C. ; Carucci, G. ; Minervini, M. ; D'Aloise, A. ; Malinconico, A. ; Aguglia, E. ; De Vanna, R. ; D'Aronco, R. / Clinical activity and tolerability of trazodone, mianserin, and amitriptyline in elderly subjects with major depression : A controlled multicenter trial. In: Clinical Neuropharmacology. 1989 ; Vol. 12, No. SUPPL. 1.
@article{f898b5f791584e2ab8929ba50a587cda,
title = "Clinical activity and tolerability of trazodone, mianserin, and amitriptyline in elderly subjects with major depression: A controlled multicenter trial",
abstract = "The aim of this multicenter study was to compare trazodone (TRA) with two reference drugs, amitriptyline (AMI) and mianserin (MIA), under double-blind conditions, in an elderly population, to ascertain age-related patterns for efficacy and tolerability. One hundred six elderly depressed inpatients, ranging in age from 60 to 83 years, diagnosed as having major depression according to DMS-III, were treated with 75 mg AMI (37 patients), 60 mg MIA (33 patients) or 150 mg TRA (36 patients) p.o. t.i.d. for 5 weeks. There were no differences in the clinical outcome among the three groups of patients at the end of the trial, with a significant amelioration (p <0.01) for the Hamilton Rating Scale for Depression (HRS-D) and the Geriatric Depression Scale (GDS). TRA showed a lower overall prevalence of side effects than AMI or MIA, particularly for anticholinergic (p = 0.03 vs. AMI) and cardiovascular (p = 0.05 vs. MIA) effects. For these data GDS seems to be most reliable in detecting changes in elderly depressive symptomatology; moreover a comparable therapeutic response (among the three drugs) but a better tolerance for atypical antidepressants, particularly TRA, make advisable the use of the latter drug in the elderly population.",
author = "Altamura, {A. C.} and Mauri, {M. C.} and N. Rudas and B. Carpiniello and R. Montanini and M. Perini and Scapicchio, {P. L.} and C. Hadjchristos and G. Carucci and M. Minervini and A. D'Aloise and A. Malinconico and E. Aguglia and {De Vanna}, R. and R. D'Aronco",
year = "1989",
language = "English",
volume = "12",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Clinical activity and tolerability of trazodone, mianserin, and amitriptyline in elderly subjects with major depression

T2 - A controlled multicenter trial

AU - Altamura, A. C.

AU - Mauri, M. C.

AU - Rudas, N.

AU - Carpiniello, B.

AU - Montanini, R.

AU - Perini, M.

AU - Scapicchio, P. L.

AU - Hadjchristos, C.

AU - Carucci, G.

AU - Minervini, M.

AU - D'Aloise, A.

AU - Malinconico, A.

AU - Aguglia, E.

AU - De Vanna, R.

AU - D'Aronco, R.

PY - 1989

Y1 - 1989

N2 - The aim of this multicenter study was to compare trazodone (TRA) with two reference drugs, amitriptyline (AMI) and mianserin (MIA), under double-blind conditions, in an elderly population, to ascertain age-related patterns for efficacy and tolerability. One hundred six elderly depressed inpatients, ranging in age from 60 to 83 years, diagnosed as having major depression according to DMS-III, were treated with 75 mg AMI (37 patients), 60 mg MIA (33 patients) or 150 mg TRA (36 patients) p.o. t.i.d. for 5 weeks. There were no differences in the clinical outcome among the three groups of patients at the end of the trial, with a significant amelioration (p <0.01) for the Hamilton Rating Scale for Depression (HRS-D) and the Geriatric Depression Scale (GDS). TRA showed a lower overall prevalence of side effects than AMI or MIA, particularly for anticholinergic (p = 0.03 vs. AMI) and cardiovascular (p = 0.05 vs. MIA) effects. For these data GDS seems to be most reliable in detecting changes in elderly depressive symptomatology; moreover a comparable therapeutic response (among the three drugs) but a better tolerance for atypical antidepressants, particularly TRA, make advisable the use of the latter drug in the elderly population.

AB - The aim of this multicenter study was to compare trazodone (TRA) with two reference drugs, amitriptyline (AMI) and mianserin (MIA), under double-blind conditions, in an elderly population, to ascertain age-related patterns for efficacy and tolerability. One hundred six elderly depressed inpatients, ranging in age from 60 to 83 years, diagnosed as having major depression according to DMS-III, were treated with 75 mg AMI (37 patients), 60 mg MIA (33 patients) or 150 mg TRA (36 patients) p.o. t.i.d. for 5 weeks. There were no differences in the clinical outcome among the three groups of patients at the end of the trial, with a significant amelioration (p <0.01) for the Hamilton Rating Scale for Depression (HRS-D) and the Geriatric Depression Scale (GDS). TRA showed a lower overall prevalence of side effects than AMI or MIA, particularly for anticholinergic (p = 0.03 vs. AMI) and cardiovascular (p = 0.05 vs. MIA) effects. For these data GDS seems to be most reliable in detecting changes in elderly depressive symptomatology; moreover a comparable therapeutic response (among the three drugs) but a better tolerance for atypical antidepressants, particularly TRA, make advisable the use of the latter drug in the elderly population.

UR - http://www.scopus.com/inward/record.url?scp=0024314681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024314681&partnerID=8YFLogxK

M3 - Article

C2 - 2663151

AN - SCOPUS:0024314681

VL - 12

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - SUPPL. 1

ER -